Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Go back to Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease| Along Mobile Technologies, Inc. (NASDAQ: AGMB) | Delayed: 15.83 +0.05 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.78 | 52 Week High | $0.01 | |||
| Open | $15.78 | 52 Week Low | $0.01 | |||
| Day High | $16.50 | P/E | N/A | |||
| Day Low | $15.41 | EPS | $0.00 | |||
| Volume | 117,759 | |||||
